INVO Fertility announces investor conference: what it means for INVO Fertility stock

INVO Fertility announced participation in the Lytham Partners Fall 2026 Investor Conference, with a webcast presentation scheduled for September 29, 2026. According to GlobeNewswire on September 25, 2026, management also planned one-on-one meetings during the event. The announcement matters because the company is shifting its story from a device supplier toward a broader fertility-care platform.

What the conference means

INVO Fertility said it operates four fertility clinics in the United States and continues to sell and distribute its INVOcell device to third-party clinics. The company describes INVOcell as a system that supports fertilization and early embryo development inside the body during part of the treatment process, under professional supervision.

The conference message therefore rests on two operating pillars: clinic ownership and device distribution. The same September 25, 2026 announcement said the company is targeting U.S. fertility clinics that are already profitable for its acquisition strategy, adding a specific criterion to its expansion model.

Revenue and earnings set the test

MarketBeat reported quarterly revenue of USD 2.18 million and earnings per share of USD 0.35 for the results released on August 14, 2026. The portal also listed a negative trailing twelve-month net margin of 116.29 percent, making operating scale and clinic economics central to the investment case.

MarketBeat listed annual sales of USD 6.84 million and a market capitalization of USD 2.3 million as of September 30, 2026. It also reported that the stock had declined 75.80 percent from its January 1, 2026 level by September 30, 2026, a quantified contrast between the conference narrative and the market record.

Stock identity and market setting

MarketBeat identifies the company as INVO Fertility on Nasdaq under ticker IVF, with INVO as the previous symbol. Its profile places the business in healthcare, specifically healthcare providers and services, while also describing INVOcell as the core medical technology.

Investor conference date

The September 29, 2026 webcast and the related one-on-one meetings give investors a dated reference point for management's clinic and device strategy. The next measurable test is whether the four-clinic platform can improve the USD 2.18 million quarterly revenue base while reducing the negative margin reported for the trailing twelve months.